Visceral adipose tissue visfatin in nonalcoholic fatty liver disease

Annals of Hepatology

Volumn 9, Issue 3, 2010, Pages 266-270

  Gaddipati, Radhika ^a   Mitnala, Sasikala ^a   Padaki, Nagarajarao ^b   Mukherjee, Rathindra Mohan ^a   Sekaran, Anuradha ^b   Jayaraj Mansard, Magnus ^b   Rabella, Pradeep ^b   Rao Guduru, Venkat ^b   Reddy Duwuru, Nageshwar ^b  

^a CARE Foundation   (India)

^b ASIAN INSTITUTE OF GASTROENTEROLOGY   (India)

Author keywords

Nafld; NEFA; TNF ; Visceral visfatin

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; FATTY ACID; INTERLEUKIN 6; LIVER ENZYME; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIRTUIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; IL6 PROTEIN, HUMAN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PROTEIN EXPRESSION; STEATOSIS; TISSUE LEVEL; BIOPSY; BLOOD; FATTY LIVER; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; BIOPSY; CYTOKINES; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FEMALE; HUMANS; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; LIVER; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77958103809     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31635-7     Document Type: Article

References (24)

1. Herbert TILG, Alexander RM. Role of adiponectin and PBEF/Visfatin as regulators of inflammation: involvement in obesity associated diseases. Clin Sci 2008; 114: 275-88.
2. Luk T, Malam Z, Marshall JC. Pre Beta cell colony enhancing factor (PBEF) Visfatin: A novel mediator of innate immunity. J Leukoc Biol 2008; 83(4): 804-16.
3. Samal B, Sun Y, Stearms G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel pre B cell colony enhancing factor. Mol cell Biol 1994; 14: 1431-7.
4. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/vis-fatin in mammals. Curr Opin Gastroenterol 2007; 23(2): 164-70.
5. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human sirt 1. J Biol Chem 2002; 277(47): 45099-107.
6. Mulhall BP, Ong JP, Younossi ZM. Non alcoholic fatty liver disease: An overview. J Gastroenterol Hepatol 2002; 17: 1136-43.
7. Baranova A, Gowder SJ, Schlauch K, Elariny H, Collantes R, Afendy A, Ong Janus P, et al. Gene expression of leptin, resistin and adiponectin in the white adipose tissue of obese patients with non alcoholic fatty liver disease and insulin resistance. Obes Surg 2006; 16: 1118-25.
8. Sethi JK, Vidal - Puig A. Visfatin: The missing link between intra-abdominal obesity and diabetes. Trends in Mol Medicine 2005; 11(8): 344-7.
9. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, So-han MR, et al. Plasma visfatin concentrations and fat depot specific mRNA expression in humans. Diabetes 2005; 54: 2911-6.
10. Filippatos TD, Derdemezis CS, Gazi IF, Logos K, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008; 38: 71-2.
11. Chen MP, Chung FM, Chang DM, Jack CR Tsai, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-9.
12. Park BJ, Kim YJ, Kim DH, Kim W, Jung YJ, Yoon JH, Kim CY, et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol 2008; 23(6): 900-7.
13. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, et al. Adipokines and cytokines in nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27(5): 412-21.
14. Aller R, De Luis DA, Izaola O, Sagrado MG, Conde R, Velas-co MC, Alvarez T, et al. Influence of visfatin on histopa-thological changes of non-alcoholic fatty liver disease. Dig Dis Sci 2009; 54: 1772-7.
15. Baranova A, Younossi ZM. Adipokines in nonalcoholic fatty liver disease. In: Fantuzzi G, Mazzone T (Ed.). Adipose tissue and adipokines in health and disease. New Jersy: Human Press; 2007, p. 291-305.
16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Te-tri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gas-trol 1999; 94: 2467-74.
17. De Boer JF, Matthias JB, Klaus H.W, Manns MP, Tietge UJF. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G196-G201.
18. Aller R, De Luis DA, Fernandez L, Calle F, Veloys B, Olcoz JL, Izaola O, et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dis Sci 2008; 53(4): 1088-92.
19. Alghasham AA, Barakat YA. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macro angiopathy. Saudi Med J 2008; 29: 185-92.
20. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004; 40(1): 46-54.
21. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH. A pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38(2): 413-9.
22. Li L, Yang G, Shi S, Yang M, Liu H, Boden G. The adipose triglyceride lipase, adiponectin and visfatin are downre-gulated by tumor necrosis factor-alpha (TNF-alpha) in vivo. Cytokine 2009; 45(1): 12-9.
23. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, Na-gaoka S, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006; 26: 39-45.
24. Beltowski J. Apelin and visfatin: unique beneficial adipokines upregulated in obesity? Med Sci Monit 2006; 12: 112-9.